Pfizer to Create Biotech Hub in China

 
 

Global pharmaceutical giant Pfizer is set to open a new biotech hub in Hangzhou.

Bloomberg report that the $350 million facility will open by 2018, and will be Pfizer's first biotechnology centre in Asia.

Meanwhile, Reuters suggest that the investment could represent an effort by Pfizer to capture a larger share of China's healthcare market. They estimate that this could be worth $158 billion by 2018.

Pfizer's current research and development facilities are in the USA, with the exception of UK sites in Cambridge and Sandwich.





Related Articles
 
 
UK and China sign health deal

 

News | July 31,2017

 
 
Chinese healthcare coming to Wales

 

News | March 07,2017

 




Playing Spectrum Sino